Acquiring Company
Samsung Biologics
Acquired Company
PolyPeptide Group AG
South Korea
SwitzerlandManufacturingBiotechnologyManufacturingBiotechnologyDescription
Samsung Biologics has secured a 98% stake in PolyPeptide, moving toward a full takeover. The move is part of Samsung Biologics' push to expand its presence in the global biopharmaceutical manufacturing market. The deal strengthens Samsung's capabilities in peptide and oligonucleotide production.
Who to call at Samsung Biologics, and when
When Samsung Biologics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Samsung Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Samsung Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Samsung Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Samsung Biologics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired PolyPeptide Group AG?
PolyPeptide Group AG was acquired by Samsung Biologics, based in South Korea. The deal was reported on November 2, 2026. Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. Samsung Biologics is privately held and operates in Manufacturing.
When did Samsung Biologics acquire PolyPeptide Group AG?
Samsung Biologics's acquisition of PolyPeptide Group AG was reported on November 2, 2026. Samsung Biologics has secured a 98% stake in PolyPeptide, moving toward a full takeover. The move is part of Samsung Biologics' push to expand its presence in the global biopharmaceutical manufacturing market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does PolyPeptide Group AG do?
PolyPeptide Group AG is a prominent contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). It is privately held, operating in Manufacturing, and is based in Switzerland.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.